Clinical pharmacokinetics of Itraconazole;Klinische Pharmakokinetik von Itraconazol

Krankenhauspharmazie

Volumn 17, Issue 8, 1996, Pages 388-395

  Lipp, Hans Peter ^a,b,c,d  

^a Universitatsapotheke Tubingen ^*  (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c Institut fur Toxikologie   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

drug monitoring; hydroxyitraconazole; interindividual variation; Itraconazole

Indexed keywords

ASTEMIZOLE; CARBAMAZEPINE; CYCLOSPORIN; DIGOXIN; DILTIAZEM; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MIDAZOLAM; NIFEDIPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; RIFAMPICIN; TACROLIMUS; TERFENADINE; TRIAZOLAM; VERAPAMIL; VINBLASTINE; VINCRISTINE; VINDESINE; WARFARIN;

ANTIFUNGAL ACTIVITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG MONITORING; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACOKINETICS; REVIEW;

EID: 0029768797     PISSN: 01737597     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Anaissie EJ. Prevention of fungal infections in cancer patients Can J Infect Dis 1995;6(Suppl C):Abstract 0584.
2. Back J, Tjia JF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharm 1991;32:624-6.
3. Barone JA, Koh JG, Bierman RH. Food Interaction and steady state pharmacokinetics nf itracunazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993;37:778-84.
4. Bhandari V, Narang A. Oral itraconazole therapy for disseminated candidiasis in low birth weight infants [letter]. J Pediatr 1992;120:330.
5. Boelart J, Schurgers M, Matthys E, et al. Itraconazole pharmacokinetics in patients with renal dysfunction. Antimicrob Agents Chemother 1988;32:1595-7
6. Boogaerts MA, Verhoef GE, Zachee P, et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989;32(Suppl1):103-8.
7. Bradford CR, Prentice AG, Warnook DW, Copplestone JA. Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission for acute myeloblastic leukemia J Antimicrob Chemother 1991;28: 555-60.
8. Butman SJ, Wild JC, Nolan PE. Prospective study of the safety and financial benefit of ketoconazole as adjunctive therapy to cyclosporine after heart transplantation. J Heart Lung Transplant 1991;10:351-8.
9. Cartledge JD, Midgley J, Youle M, Gazzard BG. Itraconazole-cyclodextrin solution - effective treatment for HIV-related candidosis unresponsive to other azole therapy. J Antimicrob Chemother 1994;33:1071-3.
10. Cauwenberg G. Cryptococcal meningitis; the place of itraconazole. Mycoses 1990;36:221-8.
11. Cauwenberg G. Pharmacokinetics of itraconazole. Mycoses 1994,37(Suppl 2) 27-33.
12. Chin TW, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Agents Chemother 1995; 39:1671-5.
13. Cleary JD, Taylor JW, Chapman SW. Itraconazole in antifungal therapy Ann Pharmacother 1992;26:502-9.
14. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy N Engl J Med 1994; 330:263-72
15. Coronel B, Persat F, Dorez D, et al Itraconazole concentrations during continuous haemodiafiltration. J Antimicrob Chemother 1994;34: 448-9.
16. Degreef HJ, DcDoncker PR. Current therapy of dermatophytosis. J Am Acad Dermatol 1994; 31:S25-30.
17. DeHart DJ. Use of itraconazole for treatment of sporotrichosis involving a knee prothesis. Clin Infect Dis 1995;21:450.
18. Denning DW, Tucker RM, Hanson LH, Hamilton JR, et al. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med 1989,149.2301-8.
19. Denning DW, Tucker RM. Hanson LH, Stevens DA. Treatment of invasive aspergillosis with itraconazole. Am J Med 1989;86:791-800.
20. Denning DW, Tucker RM, Hostetler JS, Gill S, et al. Oral itraconazole therapy of cryptococcal meningitis and cryptococcosis in patients with AIDS. In: Van den Bossche H, Mackenzie DWR, Cauwenberg G, Drouhet E, et al., editors. Mycoses in AIDS patients. New York: Plenum Press, 1990:305-24.
21. Denning DW, Van Wye J, Lewiston NJ, Stevens DA. Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole. Chest 1991;100:813-9.
22. Denning DW, Lee JY, Hostetler JS, Pappas P, et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994;97:135-44.
23. Dupont B, Drouhet E. Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results. Rev Infect Dis 1987;9(Suppl 1):S71-6.
24. First MR, et al. Safety and efficacy of long-term cyclosporine-ketoconazole-administration and preliminary results of a randomized trial. Transplant Proc 1993,25.591-4.
25. Fricke U, Klaus W. Neue Arzneimittel 1991/92: Itraconazol Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1992:117-29.
26. Grant SM, Clissold SP. Itraconazole - A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in superficial and systemic mycoses. Drugs 1989;37:310-44.
27. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994,30:911-33.
28. Hardin TC, Graybill JR, Fetchick TC, et al. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1988;32:1310-3
29. Heykants et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989; 32(Suppl 1):67-87.
30. Hoeprich PD Antifungal Chemotherapy. In: Jucker E, editor. Progress in Drug Research. Basel: Birkhäuser Verlag, 1995:87-128.
31. Hostetler JS, Hanson LH, Stevens DA. Effect of hydroxypropyl-ß-cyclodextrin on efficacy of oral itraconazole in disseminated murine cryptococcosis. J Antimicrob Chemother 1993;32:459-63.
32. Hostetler JS, et al. Discrepancies in bioassay and chromatography determinants explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations. Antimicrob Agents Chemother 1993; 37:2224-7
33. Jacobson PA, Johnson CE, Walters JR. Stability of itraconazole in an extemporaneously compounded oral liquid. Am J Health Syst Pharm 1995;52:189-91
34. Kintzel PE, Rollins CJ, Yee WJ, List AF Low itraconazole serum concentrations following administration of itraconazole suspension to critically ill allogenic bone marrow transplant recipients. Ann Pharmacother 1995;29:140-3.
35. Lake-Bakaar G, Tom W, Lake-Bakaar D. et al Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS) Ann Intern Med 1988;109:471-3
36. Law D, Moore CB, Denning DW. Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards. Antimicrob Agents Chemother 1994;38:1561-6.
37. Lazo De La Vega S, Volkow P, Yeates RA. Pfaff G Administration of the antimycotic agents fluconazole and itraconazole to leukaemia patients: a comparative pharmacokinetic study. Drugs Exptl Clin Res 1994;XX(2):69-75.
38. Lim SO, Sawyer AM, Hudson M, Sercombe J, et al. The absorption of fluconazole and itraconazole under condition of low intragastric acidity: short report. Aliment Pharmacol Ther 1993; 7.317-21.
39. Lipp HP, Schuler U, Saal J, Schaaf D Amphotericin B in Fettemulsion Vorteile gegenüber der konventionellen Therapie. Arzneimitteltherapie 1993,11:319-26.
40. Lipp HP. Schuler U. Die menschlichen Cytochrom-P450-Isoenzyrne - Bedeutung fur die klinische Praxis. Arzneimitteltherapie 1995;13:272-80
41. Miyazaki HM, Kohno S, Miyazaki Y, et al. Efficacy of intravenous itraconazole against experimental pulmonary aspergillosis. Antimicrob Agents Chemother 1993;37:2762-5.
42. Nicolau DP, Crowe H, Nightingale CH, Quinitiliani R Bioavailability of fluconazole administered via a feeding tube in intensive care unit patients. J Antimicrob Chemother 1995;36 395-401.
43. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;5:481-5.
44. Persat F, Marzullo C, Guyotat D, Rochet MJ, et al. Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment. Eur J Cancer 1992;28A:838-41.
45. Poiner JM, Lebot M, Descamps P, Levy M, et al. Determination of itraconazole and its active metabolite in plasma by column liquid chromatography. Ther Drug Monit 1994;16:596-601.
46. Prentice AG. Warnock DW, Johnson SAN, Phillips MJ, et al Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother 1994;34:247-52.
47. Prentice AG, Warnock DW, Johnson SAN, Taylor PC, et al. Multiple dose pharmacokmetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. J Antimicrob Chemother 1995;36:657-63.
48. Sachs MK, Blanchard LM, Green PJ. Interaction of itraconazole and digoxin. Clin Infect Dis 1993;16 400-3.
49. Sharkey P, Rinaldi MG, Dunn JF, Hardin TC, et al. High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother 1991;35:707-13.
50. Smith D, Van de Velde V, Woestenborghs R, Gazzard RG The pharmacokinetics of oral itraconazole in AIDS patients. J Pharm Pharmacol 1992,44:618-9.
51. 2-receptor antagonists on the pharmacokinetics of itraconazole, a new oral antifungal. Br J Clin Pharmacol 1989;27:105P-6.
52. St-Germain G, Dion C, Espinell-Ingroff A, et al. Ketoconazole and Itraconazole susceptibility of Candida albicans isolated from patients infected with HIV. J Antimicrob Chemother 1995; 36:109-18.
53. Sugar AM. Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother 1995;39:1907-12.
54. Taelman H, Boogaerts J, Kagame A. Batungwanayo J, et al. Randomized trial comparing itraconazole with amphotericin B in the primary therapy of AIDS-associated cryptococcal meningitis. International Conference of AIDS; 1993; Berlin. Abstract WS-B 12-3.
55. Tncot G, Joosten E, Boogaerts MA. Van de Pitte J, et al. Ketoconazole versus Itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results or two non-randomized studies. Rev Infect Dis 1987,9(Suppl 1):757-63
56. Tucker RM, Denning DW, Dupont B, Stevens DA. Itraconazole therapy for chronic coccidoidal meningitis. Ann Intern Med 1990;112:108-12.
57. Tucker RM, Hanson LH, Denning DW, et al The interaction of azoles with rifampin, phenytoin and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992;14:165-74.
58. Van Cutsem J. The in vitro antifungal spectrum of itraconazole. Mycoses 1989;32:7-13.
59. Van Peer A, Woestenborghs R, Heykants J, et al. The effects of food and dose on the oral systemic bioavailability of itraconazole in healthy subjects. Eur J Clin Pharmacol 1989;36:423-6.
60. Vant Wout JW. Itraconazole in neutropenic patients chemotherapy 1992;38(Suppl 1):23-6.
61. Vant Wout JW, Novakova T. Verhagen CAH, et al. The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. J Infect 1991;22:45-52.
62. Villarreal JD, Erush SC Bioavailability of itraconazole from oral liquids in question. Am J Health Syst Pharm 1995;52:1707-8.
63. Wheat J, Hafner R, Korzun AH, et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Med 1995;98:336-42.
64. Working Party of the British Society of Antimicrobial Chemotherapy: Working Party Report: Chemoprophylaxis for candidosis and aspergillosis in neutropenia and transplantation: a review and recommendations. J Antimicrob Chemother 1993;32:5-21.
65. Zimmermann T, Yeates RA, Laufen H. Pfaff G, et al. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 1994,46:147-50.